Abstract
We previously reported that uracil-tegafur with oral leucovorin (UFT/LV) treatment for elderly patients (aged ≥ 75 years) was well-tolerated in a phase II study. In the present study, the efficacy and safety of a modified (1-week shorter administration period) UFT/LV schedule combined with bevacizumab for a similar population are reported. The present study was a single-arm, open-label, multicenter, cooperative group clinical trial. The key eligibility criteria included age ≥ 75 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, first-line chemotherapy, measurable lesions, and preserved organ function. Patients received UFT 300 mg/m(2)/d and LV 75 mg/d on days 1 to 21 and intravenous bevacizumab 5 mg/kg on days 1 and 15. Treatment was repeated every 28 days. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were the objective response rate (ORR), overall survival (OS), and safety. Of the 55 patients enrolled from 15 Japanese institutions, 52 eligible patients were evaluated. Their median age was 80 years (range, 75-87 years), and 73% had an ECOG performance status of 0. The median PFS was 8.2 months (95% confidence interval [CI], 6.2-10 months). The ORR was 40% (95% C...Continue Reading
References
Mar 20, 1993·BMJ : British Medical Journal·W ScheithauerD Depisch
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardSteven E Benner
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Jul 28, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K ShiraoJ L Abbruzzese
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Jul 17, 2007·Lancet·Miriam KoopmanCornelis Ja Punt
Jul 17, 2007·Lancet·Matthew T SeymourUNKNOWN National Cancer Research Institute Colorectal Clinical Studies Group
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard S HochsterAl Bowen Benson
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Nov 12, 2009·Journal of Cancer Research and Clinical Oncology·James CassidyUlrich-Peter Rohr
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Niall C TebbuttTimothy J Price
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardJennifer Gansert
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C BokemeyerP Koralewski
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemFortunato Ciardiello
Sep 14, 2013·The Lancet Oncology·David CunninghamUNKNOWN AVEX study investigators
Feb 21, 2014·International Journal of Clinical Oncology·Toshihiko MatsumotoIchinosuke Hyodo
Citations
Mar 15, 2018·Oncotarget·Christine KochJoerg Trojan
May 16, 2019·International Journal of Clinical Oncology·Toshikazu MoriwakiIchinosuke Hyodo
Jun 17, 2019·International Journal of Clinical Oncology·Yojiro HashiguchiUNKNOWN Japanese Society for Cancer of the Colon and Rectum
Mar 29, 2020·International Journal of Clinical Oncology·Takashi OhtaTaroh Satoh
Jan 29, 2021·International Journal of Clinical Oncology·Kosuke MimaHideo Baba
Nov 16, 2016·ESMO Open·Stine Braendegaard WintherCamilla Qvortrup
Jul 31, 2018·Case Reports in Oncology·Masatsune ShibutaniMasaichi Ohira
Jan 11, 2019·Case Reports in Oncology·Masatsune ShibutaniMasaichi Ohira